Advertisement

Inflammation Research

, Volume 63, Issue 4, pp 249–254 | Cite as

The significance of YKL-40 protein in liver fibrosis

  • Hui Tao
  • Jing-Jing Yang
  • Kai-Hu Shi
  • Cheng Huang
  • Lei Zhang
  • Xiong-Wen Lv
  • Jun Li
Review

Abstract

Objective

The aims of this review are to describe the present knowledge about YKL-40 protein, discuss its relation to liver fibrosis, and to look ahead at future perspectives of YKL-40 research.

Introduction

Liver fibrosis is characterized by excess collagen deposition, decreased extracellular matrix degradation and activation of hepatic stellate cells. Therefore, advancement in the identification of liver fibrosis biomarkers with diagnostic and prognostic values becomes an important tool for future molecular therapy. The molecular basis of YKL-40 in liver fibrosis is unknown.

Methods

A PubMed database search was performed for studies of YKL-40 in liver injury and fibrosis.

Results and conclusions

YKL-40 is an inflammatory glycoprotein involved in endothelial dysfunction by promoting chemotaxis, cell attachment and migration, reorganization, and tissue remodeling as a response to endothelial damage. Several studies demonstrate that elevated serum YKL-levels are independently associated with the presence of endothelial damage and even higher YKL-40 levels are documented in liver fibrosis. YKL-40 may play a key role in liver injury and fibrosis.

Keywords

YKL-40 Liver fibrosis Hepatic stellate cell Extracellular matrix 

Abbreviations

ECM

Extracellular matrix

α-SMA

α-smooth muscle actin

HSC

Hepatic stellate cells

PPARγ

Peroxisome proliferator-activated receptor γ

Notes

Acknowledgments

This project was supported by the National Science Foundation of China (NO 81273526, 81202978), and by the Anhui Provincial Natural Science Foundation (1308085MH117).

Conflict of interest

None.

References

  1. 1.
    Chiang DJ, Roychowdhury S, Bush K, McMullen MR, Pisano S, Niese K, et al. Adenosine 2A receptor antagonist prevented and reversed liver fibrosis in a mouse model of ethanol-exacerbated liver fibrosis. PLoS One. 2013;8:e69114.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Catanzaro R, Sapienza C, Milazzo M, Arona S, Italia A, Samperi L. Liver fibrosis: evaluation with diffusion-weighted magnetic resonance imaging in patients with chronic liver disease. Minerva Gastroenterol Dietol. 2013;59:313–20.PubMedGoogle Scholar
  3. 3.
    Lee JH, Kim JC, Tae G, Oh MK, Ko DK. Rapid diagnosis of liver fibrosis using multimodal multiphoton nonlinear optical microspectroscopy imaging. J Biomed Opt. 2013;18:76009.CrossRefGoogle Scholar
  4. 4.
    Puche JE, Saiman Y, Friedman SL (2013) Hepatic stellate cells and liver fibrosis. Compr Physiol 3:1473–1492.Google Scholar
  5. 5.
    Fuchs BC, Wang H, Yang Y, Wei L, Polasek M, Schuhle DT, et al. Molecular MRI of collagen to diagnose and stage liver fibrosis. J Hepatol. 2013;59(5):992–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Delgado MG, Gracia-Sancho J, Marrone G, Rodriguez-Vilarrupla A, Deulofeu R, Abraldes JG, et al. Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2013;305(7):G496–502.PubMedCrossRefGoogle Scholar
  7. 7.
    Pijls KE, Jonkers DM, Elamin EE, Masclee AA, Koek GH. Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature. Liver Int Off J Int Assoc Study Liver. 2013;33(10):1457–69.Google Scholar
  8. 8.
    Fuster D, Tsui JI, Cheng DM, Quinn EK, Armah KA, Nunes D, et al. Interleukin-6 is associated with noninvasive markers of liver fibrosis in hiv-infected patients with alcohol problems. AIDS Res Hum Retrovir. 2013;29:1110–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Abdalla AF, Fathy A, Zalata KR, Megahed A, Abo-Alyazeed A, El Regal ME. Morphometric assessment of liver fibrosis may enhance early diagnosis of biliary atresia. World J Pediatrics WJP. 2013;9(4):330–5.CrossRefGoogle Scholar
  10. 10.
    Kornblit B, Hellemann D, Munthe-Fog L, Bonde J, Strom JJ, Madsen HO, et al. Plasma YKL-40 and CHI3L1 in systemic inflammation and sepsis-experience from two prospective cohorts. Immunobiology. 2013;218(10):1227–34.PubMedCrossRefGoogle Scholar
  11. 11.
    Konradsen JR, James A, Nordlund B, Reinius LE, Soderhall C, Melen E, et al. The chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthma. J Allergy Clin Immunol. 2013;132(2):328–35.PubMedCrossRefGoogle Scholar
  12. 12.
    Negash AA, Ramos HJ, Crochet N, Lau DT, Doehle B, Papic N, et al. IL-1beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog. 2013;9:e1003330.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Chen B, Ye B, Zhang J, Ying L, Chen Y. RDW to platelet ratio: a novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B. PLoS One. 2013;8:e68780.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Jagavelu K, Routray C, Shergill U, O’Hara SP, Faubion W, Shah VH. Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver. Hepatology. 2010;52:590–601.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Marra F, Aleffi S, Galastri S, Provenzano A. Mononuclear cells in liver fibrosis. Semin Immunopathol. 2009;31:345–58.PubMedCrossRefGoogle Scholar
  16. 16.
    Yang JJ, Tao H, Huang C, Li J. Nuclear erythroid 2-related factor 2: a novel potential therapeutic target for liver fibrosis. Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc. 2013;59C:421–7.CrossRefGoogle Scholar
  17. 17.
    Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell. 2013;153:601–13.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Tomita K, Teratani T, Suzuki T, Shimizu M, Sato H, Narimatsu K, et al. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology. 2013. doi: 10.1002/hep.26604.Google Scholar
  19. 19.
    Nevzorova YA, Hu W, Cubero FJ, Haas U, Freimuth J, Tacke F, et al. Overexpression of c-myc in hepatocytes promotes activation of hepatic stellate cells and facilitates the onset of liver fibrosis. Biochim Biophys Acta. 2013;1832:1765–75.PubMedCrossRefGoogle Scholar
  20. 20.
    Osawa Y, Hoshi M, Yasuda I, Saibara T, Moriwaki H, Kozawa O. Tumor necrosis factor-alpha promotes cholestasis-induced liver fibrosis in the mouse through tissue inhibitor of metalloproteinase-1 production in hepatic stellate cells. PLoS One. 2013;8:e65251.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Saito S, Hata K, Iwaisako K, Yanagida A, Takeiri M, Tanaka H, et al. Cilostazol attenuates hepatic stellate cell activation and protects mice against carbon tetrachloride-induced liver fibrosis. Hepatol Res Off J Jpn Soc Hepatol. 2013. doi: 10.1111/hepr.12140.Google Scholar
  22. 22.
    Yang L, Stimpson SA, Chen L, Wallace Harrington W, Rockey DC, et al. Effectiveness of the PPARgamma agonist, GW570, in liver fibrosis. Inflamm Res Off J Eur Hist Res Soc. 2010;59:1061–71.Google Scholar
  23. 23.
    Novo E, Parola M. The role of redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair. 2012;5(Suppl 1):S4.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Lv Z, Song Y, Xue D, Zhang W, Cheng Y, Xu L. Effect of salvianolic-acid B on inhibiting MAPK signaling induced by transforming growth factor-beta1 in activated rat hepatic stellate cells. J Ethnopharmacol. 2010;132:384–92.PubMedCrossRefGoogle Scholar
  25. 25.
    Li J, Li S, He B, Mi Y, Cao H, Zhang C, et al. Ameliorative effect of grape seed proanthocyanidin extract on thioacetamide-induced mouse hepatic fibrosis. Toxicol Lett. 2012;213:353–60.PubMedCrossRefGoogle Scholar
  26. 26.
    Klein S, Klosel J, Schierwagen R, Korner C, Granzow M, Huss S, et al. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab Investig J Tech Methods Pathol. 2012;92:1440–50.CrossRefGoogle Scholar
  27. 27.
    Liu C, Wang G, Chen G, Mu Y, Zhang L, Hu X, et al. Huangqi decoction inhibits apoptosis and fibrosis, but promotes Kupffer cell activation in dimethylnitrosamine-induced rat liver fibrosis. BMC Complim Altern Med. 2012;12:51.CrossRefGoogle Scholar
  28. 28.
    Bieghs V, Walenbergh SM, Hendrikx T, van Gorp PJ, Verheyen F, Olde Damink SW, et al. Trapping of oxidized LDL in lysosomes of Kupffer cells is a trigger for hepatic inflammation. Liver Int Off J Int Assoc Study Liver. 2013;33:1056–61.Google Scholar
  29. 29.
    Su LJ, Chang CC, Yang CH, Hsieh SJ, Wu YC, Lai JM, et al. Graptopetalum paraguayense ameliorates chemical-induced rat hepatic fibrosis in vivo and inactivates stellate cells and Kupffer cells in vitro. PLoS One. 2013;8:e53988.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Kinnman N, Francoz C, Barbu V, Wendum D, Rey C, Hultcrantz R, et al. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Investig J Tech Methods Pathol. 2003;83:163–73.CrossRefGoogle Scholar
  31. 31.
    Wang J, Leclercq I, Brymora JM, Xu N, Ramezani-Moghadam M, London RM, et al. Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology. 2009;137:713–23.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Harutyunyan M, Christiansen M, Johansen JS, Kober L, Torp-Petersen C, Kastrup J. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. Immunobiology. 2012;217:652–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Nielsen KR, Steffensen R, Boegsted M, Baech J, Lundbye-Christensen S, Hetland ML, et al. Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects. Arthritis Res Ther. 2011;13:R109.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Johansen JS, Jensen HS, Price PA. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol. 1993;32:949–55.PubMedCrossRefGoogle Scholar
  35. 35.
    Schimpl M, Rush CL, Betou M, Eggleston IM, Recklies AD, van Aalten DM. Human YKL-39 is a pseudo-chitinase with retained chitooligosaccharide-binding properties. Biochem J. 2012;446:149–57.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Roslind A, Johansen JS. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol. 2009;511:159–84.PubMedCrossRefGoogle Scholar
  37. 37.
    Areshkov PO, Avdieiev SS, Balynska OV, Leroith D, Kavsan VM. Two closely related human members of chitinase-like family, CHI3L1 and CHI3L2, activate ERK1/2 in 293 and U373 cells but have the different influence on cell proliferation. Int J Biol Sci. 2012;8:39–48.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Scully S, Yan W, Bentley B, Cao QJ, Shao R. Inhibitory activity of YKL-40 in mammary epithelial cell differentiation and polarization induced by lactogenic hormones: a role in mammary tissue involution. PLoS One. 2011;6:e25819.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Prakash M, Bodas M, Prakash D, Nawani N, Khetmalas M, Mandal A, et al. Diverse pathological implications of YKL-40: answers may lie in ‘outside-in’ signaling. Cell Signal. 2013;25:1567–73.PubMedCrossRefGoogle Scholar
  40. 40.
    Tache D, Bogdan F, Pisoschi C, Banita M, Stanciulescu C, Fusaru AM, et al. Evidence for the involvement of TGF-beta1-CTGF axis in liver fibrogenesis secondary to hepatic viral infection. Rom J Morphol Embryol. 2011;52:409–12.PubMedGoogle Scholar
  41. 41.
    Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Investig J Tech Methods Pathol. 2007;87:858–70.CrossRefGoogle Scholar
  42. 42.
    Rehli M, Niller HH, Ammon C, Langmann S, Schwarzfischer L, Andreesen R, et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem. 2003;278:44058–67.PubMedCrossRefGoogle Scholar
  43. 43.
    Junker N, Johansen JS, Hansen LT, Lund EL, Kristjansen PE. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci. 2005;96:183–90.PubMedCrossRefGoogle Scholar
  44. 44.
    Antonelli M, Massimino M, Morra I, Garre ML, Gardiman MP, Buttarelli FR, et al. Expression of pERK and pAKT in pediatric high grade astrocytomas: correlation with YKL40 and prognostic significance. Neuropathol Off J Jpn Soc Neuropathol. 2012;32:133–8.CrossRefGoogle Scholar
  45. 45.
    Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, Liu JL, et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12:3935–41.CrossRefGoogle Scholar
  46. 46.
    Gonzalez-Fernandez O, Jimenez A, Villalobo A. Differential p38 mitogen-activated protein kinase-controlled hypophosphorylation of the retinoblastoma protein induced by nitric oxide in neuroblastoma cells. Free Radic Biol Med. 2008;44:353–66.PubMedCrossRefGoogle Scholar
  47. 47.
    Chrissouli S, Pratsinis H, Velissariou V, Anastasiou A, Kletsas D. Human amniotic fluid stimulates the proliferation of human fetal and adult skin fibroblasts: the roles of bFGF and PDGF and of the ERK and Akt signaling pathways. Wound Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc. 2010;18:643–54.Google Scholar
  48. 48.
    Wehr A, Baeck C, Heymann F, Niemietz PM, Hammerich L, Martin C, et al. Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis. J Immunol. 2013;190:5226–36.PubMedCrossRefGoogle Scholar
  49. 49.
    Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care. 2009;32:323–8.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Berres ML, Papen S, Pauels K, Schmitz P, Zaldivar MM, Hellerbrand C, et al. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol. 2009;50:370–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Lee CK, Perez-Atayde AR, Mitchell PD, Raza R, Afdhal NH, Jonas MM. Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston Children’s Hospital Experience. J Pediatr. 2013;163(4):1058–64.PubMedCrossRefGoogle Scholar
  52. 52.
    Cassol E, Misra V, Holman A, Kamat A, Morgello S, Gabuzda D. Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis. 2013;13:203.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Eurich D, Neumann UP, Boas-Knoop S, Neuhaus R, Kiessling A, Yahyazadeh A, et al. YKL-40-gene polymorphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis C virus-induced liver disease. J Gastroenterol Hepatol. 2013;28:153–60.PubMedCrossRefGoogle Scholar
  54. 54.
    Wang D, Lu JG, Wang Q, Du XL, Dong R, Wang P, et al. Increased immunohistochemical expression of YKL-40 in the spleen of patients with portal hypertension. Braz J Med Biol Research. 2012;45:264–72.CrossRefGoogle Scholar
  55. 55.
    Lebensztejn DM, Wierzbicka A, Socha P, Pronicki M, Skiba E, Werpachowska I, et al. Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease. Acta Biochim Polonica. 2011;58:563–6.Google Scholar
  56. 56.
    Fontana RJ, Litman HJ, Dienstag JL, Bonkovsky HL, Su G, Sterling RK, et al. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int Off J Int Assoc Study Liver. 2012;32:665–74.CrossRefGoogle Scholar
  57. 57.
    Pizano-Martinez O, Yanez-Sanchez I, Alatorre-Carranza P, Miranda-Diaz A, Ortiz-Lazareno PC, Garcia-Iglesias T, et al. YKL-40 expression in CD14(+) liver cells in acute and chronic injury. World J Gastroenterol WJG. 2011;17:3830–5.CrossRefGoogle Scholar
  58. 58.
    Rath T, Roderfeld M, Guler C, Wenzel C, Graf J, Beitinger F, et al. YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis. Scand J Gastroenterol. 2011;46:1369–80.PubMedCrossRefGoogle Scholar
  59. 59.
    Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, et al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut. 2010;59:1401–9.PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Schiavon LL, Carvalho-Filho RJ, Narciso-Schiavon JL, Medina-Pestana JO, Lanzoni VP, Ferraz ML, et al. YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection. Scand J Gastroenterol. 2010;45:615–22.PubMedCrossRefGoogle Scholar
  61. 61.
    Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, et al. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2009;7:219–26.Google Scholar
  62. 62.
    Pungpapong S, Nunes DP, Krishna M, Nakhleh R, Chambers K, Ghabril M, et al. Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2008;14:1294–302.Google Scholar
  63. 63.
    Mehta P, Ploutz-Snyder R, Nandi J, Rawlins SR, Sanderson SO, Levine RA. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol. 2008;103:928–36.PubMedCrossRefGoogle Scholar
  64. 64.
    Lebensztejn DM, Skiba E, Werpachowska I, Sobaniec-Lotowska ME, Kaczmarski M. Serum level of YKL-40 does not predict advanced liver fibrosis in children with chronic hepatitis B. Adv Med Sci. 2007;52:120–4.PubMedGoogle Scholar
  65. 65.
    Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology. 2008;47:789–98.PubMedCrossRefGoogle Scholar
  66. 66.
    Esmat G, Metwally M, Zalata KR, Gadalla S, Abdel-Hamid M, Abouzied A, et al. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol. 2007;46:620–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Kamal SM, Turner B, He Q, Rasenack J, Bianchi L, Al Tawil A, et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology. 2006;43:771–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Zheng M, Cai WM, Zhao JK, Zhu SM, Liu RH. Determination of serum levels of YKL-40 and hyaluronic acid in patients with hepatic fibrosis due to schistosomiasis japonica and appraisal of their clinical value. Acta Trop. 2005;96:148–52.PubMedCrossRefGoogle Scholar
  69. 69.
    Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol WJG. 2005;11:476–81.Google Scholar
  70. 70.
    Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2006;15:194–202.CrossRefGoogle Scholar

Copyright information

© Springer Basel 2014

Authors and Affiliations

  1. 1.Department of Cardiothoracic SurgeryThe Second Hospital of Anhui Medical UniversityHefeiChina
  2. 2.Cardiovascular Research CenterAnhui Medical UniversityHefeiChina
  3. 3.School of PharmacyAnhui Medical UniversityHefeiChina
  4. 4.Department of PharmacologyThe Second Hospital of Anhui Medical UniversityHefeiChina

Personalised recommendations